Drug product launch

During product launch and steady-state production, the purifications goal is to treat large amounts of racemate (> 25 tons per year) with total process costs well under the targeted kg drug product price. Moreover, the purifications process must be robust and easy to operate. 

Drug Launches. Drug Launches [66] records and documents new product launches throughout the world. Data are compiled directly by 60 IMS companies located throughout the major markets of the world. Each entry records trade names, active ingredients, marketing companies, pack information, launch date, indication, and therapy class. This product is commercially available in several formats. 

An autoimmune response is rarely detected during preclinical drug development because of the lack of good predictive animal models for the human immune system. Owing to their low incidence and idiosyncratic nature, autoimmune diseases quite often appear as a serious issue only after product launch [2,22]. 

Ritonavir is a product of Abbott Laboratories Ltd. for the treatment of HIV and is marketed as Norvir , in liquid and semisolid capsule formulations. It received FDA approval for market launch in march 1996, at which time only one polymorphic form of Ritonavir (Form I) was known. Two years later in early 1998 a laboratory responsible for testing the formulated product in the US reported dissolution test failures of the semisolid capsules, and noted that drug product had precipitated out of solution. A new polymorphic form had been discovered that was thermodynamically more stable than the existing form and approximately 5 times less soluble in the formulation. Figure 7. 

Third, a more rapid rafe of sales erosion in brand name producfs was observed in fhe case of more recenf pafenf expirations. This is especially so for fhe fop selling drug products which attract the most intensive generic competition. Three recent cases illustrate this phenomenon. Generic enalapril, laxmched in August 2000 as a substitute for the brand name drug Vasotec , obtained 66.4% of new prescriptions just 4 weeks after its launch. 

A question I am consistently asked about funding a biotech company is, "What kind of investor can afford to accept the extremely high technical risk of drug development while waiting 10 to 15 years for a product launch "... 

Once an NDA is approved and the drug product is successfully launched, corporate resources shift to production, storage, distribution and marketing of the drug product. The quality and integrity of the drug... 

New drug launches The new R D technologies adopted by pharma come to fruition and revert the <-slump in new product launches Pharma does not succeed in collecting the high-hanging fruit, and more stringent rules (e.g.,economic ones) further hamper new product launches... 

From the foregoing discussion, there are clearly many issues to be confronted when scaling up the pan-coating process. Evidently, the more definitive data that are developed initially, the less likely that major problems will occur later on, especially problems that could inevitably delay a product launch and cost much in the way of lost revenues, particularly when dealing with a potentially blockbuster drug product. 

Analytical potency method development should be performed to the extent that it is sufficient for its intended purpose. It is important to understand and know the molecular structure of the analyte during the method development process, as this will facilitate the identification of potential degradation impurities. For example, an impurity of M + 16 in the mass spectrum of a sample may indicate the probability of a nitrogen oxide formation. Upon successful completion of method development, the potency method will then be validated to show proof that it is suitable for its intended purpose. Finally, the method validated will be transferred to the quality control laboratory in preparation for the launch of the drug substance or drug product. 

This chapter has been divided into three distinct sections, all of which focus on a forward quality perspective to ensure that the highest level of quality assurance (QA) and durable compliance is maintained throughout the drug development process, during initial product launch, and after the product has been commercialized. 

Naproxen was introduced to the market by Syntex in 1976 as a nonsteroidal antiinflammatory drug (NS AID) in an optically pure form. The original manufacturing process (Scheme 6.1) before product launch started from P-naphthol (1), which was brominated in methylene chloride to produce 1,6-dibromonaphthol (2). The labile bromine at the 1-position was removed with bisulfite to give... 

Attributes Clinical Evaluation and Drug Product Development (END) Approval and launch... 

Marketing to continue evaluating the status of competitor s drug candidates and the potential of the developmental candidate to fill a medical need and to prepare for product launch... 

Despite the sharp increase in development cost, the number of new products launched and their sales expectations remained fairly constant (Lumley and Walker, 1992). It has been calculated that in the UK even the best selling 10% new drugs require longer than the effective life-span of their patents to recover the research and development cost the majority of new pharmaceuticals cannot recoup these cost even after more than 20 years (Prentis et al., 1988). 

The pharmaceutical industry must invest more in research and development than any other industry to discover innovative drugs and therapies to fulfill medical needs. Because of the high R D cost and to meet growth expectations and goals for new product launches, many companies are constantly reorganizing their research operations to be more effective [1]. 

---